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Tobacco cessation after cancer diagnosis leads to better patient outcomes. However,
tobacco treatment services are frequently unavailable in cancer care settings, and
multilevel implementation challenges can impede uptake of new programs. The
National Cancer Institute (NCI) dedicated Cancer Moonshot funding through the Cancer
Center Cessation Initiative (C3I) for NCI-Designated Cancer Centers to implement or
enhance the implementation of tobacco treatment services. We examined a pragmatic
application of the RE-AIM framework (reach, effectiveness, adoption, implementation,
and maintenance) to evaluate tobacco treatment programs implemented within Cancer
Centers funded through C3I. Using three C3I-funded Centers as examples, we describe
how each RE-AIM construct was operationalized to evaluate the implementation of
a wide range of cessation services (e.g., tobacco use screening, counseling, Quitline
referral, pharmacotherapy) in this heterogeneous group of cancer care settings. We
discuss the practical challenges encountered in assessing RE-AIM constructs in real
world situations, including using the electronic health record (EHR) to aid in assessment.
Reach and effectiveness evaluation required that Centers define the setting(s) where
cessation services were implemented (to determine the “denominator”), enumerate the
patient population, report current patient tobacco use, patient engagement in tobacco
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treatment, and 6-month cessation outcomes. To reduce site heterogeneity, increase
data accuracy, and reduce burden, reach was frequently captured via standardized
EHR enhancements that improved the identification of current smokers and tobacco
treatment referrals. Effectiveness was determined by cessation outcomes (30-day point
prevalence abstinence at 6-months post-engagement) assessed through a variety
of data collection approaches. Adoption was measured by the characteristics and
proportion of targeted cancer care settings and clinicians engaged in cessation
service delivery. Implementation was assessed by examining the delivery of tobacco
screening assessments and intervention components across sites, and provider-level
implementation consistency. Maintenance assessments identified whether tobacco
treatment services continued in the setting after implementation and documented the
sustainability plan and organizational commitment to continued delivery. In sum, this
paper demonstrates a pragmatic approach to using RE-AIM as an evaluation framework
that yields relevant outcomes on common implementation metrics across widely differing
tobacco treatment approaches and settings.
Keywords: Tobacco treatment, Smoking Cessation, Cancer center, RE-AIM (Reach, Effectiveness, Adoption,
Implementation and Maintenance), implementation
INTRODUCTION
Continued smoking after a cancer diagnosis has been associated
with adverse outcomes, including overall and cancer specific
mortality, and increased risk of developing a second primary
cancer. Importantly, smoking cessation after a cancer diagnosis
improves clinical outcomes (1, 2). Several national cancer
organizations have developed recommendations for integrating
tobacco treatment as a routine component of cancer care (3–6).
All patients seen in cancer care should be consistently assessed
for tobacco use, and if they are current users (usually past 30
day use), should be advised to quit, and/or referred to cessation
treatment (6, 7). While the recommendations are clear for what
to implement, there is little published on how to implement and
evaluate tobacco treatment programs in cancer care settings (7).
Despite the availability of the National Comprehensive Cancer
Network (NCCN) (6) and other Clinical Practice Guidelines for
Smoking Cessation, tobacco treatment services are often not a
routine component of cancer care (8–10).
To address this gap in research-to-practice, the National
Cancer Institute (NCI) dedicated Cancer Moonshot funding to
enhance the capacity of NCI-Designated Comprehensive Cancer
Centers to implement sustainable evidence-based tobacco
treatment programs (11). The resulting Cancer Center Cessation
Initiative (C3I) funded 42 NCI-Designated Comprehensive
Cancer Centers (“Centers”) to integrate tobacco treatment into
cancer care. The C3I provides a unique opportunity to examine
how tobacco treatment can be effectively implemented in cancer
care. This study uses the RE-AIM framework (12) to evaluate
how different tobacco treatment programs were implemented in
diverse real-world clinical settings receiving the same level of
supplemental funding (11).
RE-AIM has been used previously to evaluate tobacco
treatment programs in healthcare settings (13, 14). However
some elements of the framework, namely adoption,
implementation, and maintenance, are often not reported
(15, 16), and most published studies report on measures
collected as part of a research study rather than a pragmatic
application in multiple, diverse clinical settings. This paper
provides examples of a pragmatic application of the RE-AIM
framework to evaluate the implementation of real-world tobacco
treatment programs in cancer care settings using simple, low
burden measures easily gathered across clinical settings using
electronic health records (EHRs) to aid in measurement (12, 17).
CANCER CENTER CESSATION INITIATIVE
PRAGMATIC RE-AIM APPLICATION
The C3I funded 42 Cancer Centers from 28 states and the
District of Columbia for 2 years to implement evidence-
based tobacco treatment programs through a supplement to
the Cancer Center Support Grant (11). The C3I Coordinating
Center provides scientific and technical assistance to help Centers
integrate tobacco treatment services into clinical care. The
goals were to: (1) achieve consistent tobacco use screening and
documentation for every patient; and (2) deliver evidence-based
tobacco treatment to current smokers, ideally using the EHR
to streamline referrals. Centers were free to choose evidence-
based intervention components for their sites, including referrals
to internal (e.g., counseling, medication) and external (e.g.,
Quitline) programs.
The C3I Coordinating Center, in collaboration with an
expert panel of physicians, psychologists, and behavioral
scientists with clinical and implementation expertise in smoking
cessation for cancer patients, developed measures to evaluate
progress amongst the C3I Centers. Measures were drawn
from a pragmatic application of the RE-AIM framework and
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intended to be low burden, actionable, sensitive to change,
and broadly applicable to diverse cancer care settings (12).
Figure 1 shows the RE-AIM application to evaluate tobacco
treatment program implementation, the evidence-based program
components implemented, and the related implementation steps
employed. Measures were designed to be compatible with
existing EHR functionalityto generate data for evaluation. The
Coordinating Center facilitated the sharing of best practices
across C3I sites, and created a learning environment where sites
meet every 6 months to discuss their successes and challenges,
including reporting on the evaluation of their program
implementation. Coordinating Center recommendations to the
C3I Centers for how each RE-AIMmeasure might be interpreted
and used is presented below.
Reach
Reach in C3I is defined as the proportion of current smokers
seen in a cancer care setting who engaged or participated
in an evidence-based tobacco treatment program. However,
calculating reach is dependent upon the consistent identification
of current smokers in the EHR (i.e., the denominator for
reach) and upon the definition and documentation of patient
engagement in an evidence-based tobacco treatment program
(i.e., the numerator for reach). The following steps were offered to
guide the assessment of reach by using the EHR to determine the
numerator and denominator for the reach of tobacco treatment
programs in cancer care settings. Table 1 shows the results for
three NCI-Designated Cancer Centers in C3I.
1. Define the setting where patients are assessed for tobacco use
and identified as current smokers during their medical visit
(e.g., the whole cancer center, or certain clinics).
2. Count unique patients seen in the setting during a specific
period (e.g., 6 months). Each Center determined the type
of visit in which tobacco use assessment would occur, such
as during registration or nursing assessment, and were
encouraged to include patients seen for cancer screening
or treatment. The EHR reporting team may need to set
up filters for selecting patient encounters and/or rules for
counting visits. The aim is to select visits with clinician-patient
interactions where tobacco use assessment and referrals
should occur for current smokers.
3. Count the number of patients screened for tobacco use to
determine the tobacco use assessment rate (number of patients
screened/total number of patients).
4. Determine the number of current smokers by counting
patients with a current smoking status. In the EHR a current
smoking status could include: current every day smoker;
current some days smoker; heavy smoker; or light smoker, but
may vary depending on how the EHR is programmed. This
number serves as the denominator for reach.
5. Among current smokers, count the number who engaged in
at least one type of evidence-based tobacco treatment, and the
number who engaged in each type of treatment offered at the
Center. This serves as the numerator for reach. Each Center
defined engagement depending on the services offered and
following these guidelines for what constitutes engagement:
a. counseling (in-person, phone, including brief advice
to quit),
b. connection to a Quitline, web-based, or text/mobile
program via fax or eReferral, or
c. cessation medications prescribed.
If a program counts acceptance to receive treatment (e.g.,
to be referred to a Quitline) as engagement, reach should be
defined as such. The number of smokers who were offered
a program should be recorded separately from those who
did engage. This could include the number of smokers who
were offered enrollment in a counseling program (regardless
of engagement), or the number who were given educational
materials but were not connected with a program. The number
of current smokers who declined to participate should be
documented as a target for quality improvement.
6. Wherever possible, each Center should record patient
demographics for current smokers and program participants
to determine the representativeness of those reached. Many
EHRs capture data on patient gender, race, ethnicity, age, and
primary insurance type.
Effectiveness
Effectiveness is assessed by examining quit rates among those
who participate in cessation treatment. In C3I, outcomes are
assessed at 6-months post-engagement with one item; “When
did you last smoke a cigarette (even one or two puffs)?,”
which allows for the calculation of both 7- and 30-day point
prevalence abstinence rates. Documentation may occur in a
separate database or within the EHR, although this may
require additional programming. Follow-up assessments can be
conducted in-person, via telephone, or through Quitline reports.
In line with reach, effectiveness should be examined by patient
sociodemographics and the type of tobacco treatment program
used to explore variation in cessation outcomes.
Adoption
Setting level adoption is defined as the proportion of settings
targeted for implementation that initiated the program.
Adoption can be examined by organizational characteristics to
understand local barriers. For example, are the administrative
leaders in some settings hesitant to make changes to the
EHR, or is there high staff turnover that makes clinical
leadership hesitant to devote time to staff training? Provider
level adoption can be assessed by documenting participation
in training and tracking initiation of program components.
Examining which implementation steps facilitated adoption
(e.g., securing buy-in, provider trainings) should suggest
how tobacco treatment can be enhanced at the setting and
provider level.
Implementation
Level of implementation can be indexed by the quality
and consistency of tobacco treatment service delivery.
Examining provider level tobacco use screening, advice
and referral rates can identify high- and low-performing
providers, which can be used to focus additional training.
Intervention fidelity can be assessed by examining the delivery
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FIGURE 1 | RE-AIM application to evaluate tobacco treatment program implementation in cancer care, and the related implementation steps and evidence-based
intervention components employed.
of intervention components, such as brief advice, counseling
sessions delivered as intended, and whether medications were
prescribed. Such information can be used to understand
the sources of variation in intervention effectiveness: (i.e.,
is it the intervention or is it the level of implementation?)
Qualitative methods, such as stakeholder interviews with
patients, clinicians, and administrators can be used to examine
barriers to implementation.
Maintenance
Maintenance can be defined as the degree to which rates of
reach and effectiveness are sustained across time, as well as
the potential for sustainability of the program. Defining the
sustainability plan and securing organizational commitment
to the program are key elements in estimating sustainability
potential. After implementation, the number of settings
in which the program is continued can be assessed, with
a qualitative examination of the reasons programs were
not maintained, with a comparison of maintained/not
maintained settings on organizational, provider, and
patient characteristics.




The EHR-enabled Evidence-based Smoking Cessation Treatment
(ELEVATE) program developed at Washington University was
implemented at the Siteman Cancer Center, which serves
about 25,000 patients per year across rural and urban areas
and medically underserved populations in multiple Midwestern
states. The implementation of ELEVATE coincided with the
launch of a new EHR platform at Washington University and
BJC Healthcare system. ELEVATE leverages newly developed
EHR modifications, including enhanced clinical workflows,
Best Practice Alerts (BPAs), and automated referral systems to
prescribe smoking cessation medications and provide counseling
resources at the point-of-care (Table 1). Patients with a status of
current smoker or a prescription for cessation medication are
defined as “current smokers,” which triggers a BPA prompting
the clinician to deliver brief advice, prescribe medications, and
refer patients to “light-touch” resources including the Quitline,
SmokefreeTXT, and Smokefree smartphone apps.
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TABLE 1 | Description of tobacco treatment programs at three NCI-Designated Cancer Centers funded through the Cancer Center Cessation Initiative.
Washington University Yale University Case Western Reserve University
Setting (s) Siteman Cancer Center, St. Louis, MO Smilow Cancer Hospital, New Haven, CT
and Smilow Cancer Care Centers
throughout CT
University Hospitals Seidman Cancer
Center, MetroHealth Cancer Center,
Cleveland Clinic Taussig Cancer Center,
Cleveland, OHb



















• Deliver smoking cessation counseling
(5A’s) and pharmacotherapy at the point
of care.
• Enhance the EHR to identify and refer
current smokers to the Quitline and
SmokefreeTXT.
• Training and video-based
demonstrations and simulated patient
scenarios with clinical care providers
using test patients in the EHR.
• Monthly provider performance data
feedback, in comparison to
department- and/or clinic-level data and
clinical benchmarks.
Tobacco Treatment Service (TTS) at
Smilow Cancer Hospital
• In-person counseling program including
medication management, and training
providers.
• Phone/tele-health counseling also
delivered.
• Smokers are also referred to
SmokefreeTXT.
• Monthly audit and feedback reports on
Care Center performance are prepared
and reviewed by the Tobacco Treatment
Service and shared with Smilow Cancer
Hospital and Care Center leadership.
Tobacco Intervention & Psychosocial
Support (TIPS) Service
• Face-to-face cognitive behavioral
therapy combined with
pharmacotherapy.
• Tailored to cancer patients by including
cancer-specific psychoeducation,
emotional vulnerability content, and
flexible intervention formats (e.g.,
in-clinic, telephone).
• Caregivers and/or significant others may
also be treated.




• Current smokers identified through the
EHR during visit.
• Patients with a current smoker status or
documented as using a cessation
medication will trigger a BPA that
prompts the clinician to deliver
counseling and pharmacotherapy at the
point-of-care.
• Referrals to the Quitline and
SmokefreeTXT generated through
the EHR.
• Current smokers identified through the
EHR.
• A list of current smokers sent to
program staff who contact patients to
schedule appointments.
• eReferral to SmokefreeTXT is
in development.
• Current smokers identified through the
EHR during visit. Patients who indicate
motivation to quit are referred via email,
pager, or through eReferral (in select
clinics).
• Patients are contacted by TIPS staff
for the initial assessment, treatment
planning, and schedule for counseling
appointments.
• Patients may be signed up for
SmokefreeTXT by program staff or
may self-enroll.
• Caregivers/significant others may be
seen with the patient or contacted
independently by program staff
EHR modifications
implemented
Developed new clinical workflow, BPAs,
and eReferral systems.
• Modified clinical workflow.
• Enhanced the EHR to standardize
tobacco use assessment.
• eReferral sends prompt to Tobacco
Treatment Service for current smokers.
• Standardized tobacco use assessments
based on NCCN guidelines.
• EHR provider notes generated to
summarize tobacco treatment services
delivered.
• EHR eReferral generated to send
patient information to TIPS
aReported for a 6-months period at 1 year post-implementation.
bSum across the three healthcare systems.
The ELEVATE program is supported by a bundled
implementation strategy that includes: formal and informal
training exercises through in-person and video-based
demonstrations of ELEVATE module use, technical assistance
and recommendations following live patient encounters and
simulated patient scenarios with clinical care providers using test
patients in the EHR, and monthly performance data feedback
delivered to medical assistants and physicians that provides
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data on assessment and treatment rates at the provider level
and in comparison to department- and/or clinic-level data and
clinical benchmarks. With the emphasis on data-driven quality
improvement, provider-level assessment and treatment rates are
expected to increase over time.
Reach
Smoking prevalence was 12.5% among patients screened for
tobacco use who had at least one outpatient oncology clinic
visit within a 6-month period (Table 2). Reach was defined as
the proportion of current smokers who received either of the
following types of tobacco treatment documented in the EHR
within a 6-month period: active smoking cessation medication
prescribed (i.e., medication rate) or brief cessation counseling
(i.e., brief counseling rate). Before ELEVATE implementation,
overall reach was 3.6%; after implementation, reach increased
to 43.1%. Interest in counseling (i.e., counseling offer rate), and
referral to phone-based, SMS text-based, and/or smartphone
app-based counseling (i.e., counseling referral rate) were
recorded separately from engagement.
Effectiveness
The EHR was used to assess current smoking status at 6-months
post-tobacco treatment. This method relied on patients having an
updated tobacco use status at 6-months after receiving tobacco
treatment. Using this method, 67.2% of patients that received
tobacco treatment had follow-up data available in the EHR in the
following 6 months. Before ELEVATE was implemented, EHR
data indicated that only 2.3% of patients treated for smoking
had not smoked in the past 30 days at 6-months post-treatment.
Following ELEVATE, 43.9% of smokers who received brief
counseling, medications, or both and who had 6-month follow-
up data documented in the EHR had not smoked in the past
30 days (29.5% using an intent to treat principle counting those
lost to follow-up as current smokers). In contrast, only 7.6% of
smokers who did not receive tobacco treatment reported they
were no longer current smokers 6-months following their cancer
center visit.
Adoption
At the setting level, all 21 outpatient oncology clinics in
the Siteman Cancer Center adopted ELEVATE and initiated
tobacco assessment and treatment services with the new point-
of-care EHR module. At the provider level, at 1-year post-
implementation, EHR data revealed that 99% of providers/clinic
staff had initiated use of the new smoking status assessment,
79% initiated medication documentation, and 85% initiated the
counseling referral components of ELEVATE, indicating high
levels of adoption.
Implementation
The tobacco use assessment rate was 93% over a 6-month period
1 year after implementation. In contrast, the assessment rate was
only 47.9% in the 5 months preceding the ELEVATE launch
(18). Provider-level rates of assessment and treatment varied
substantially. Over a 6 month period, 93% of medical assistants
documented tobacco use assessment for at least 90% of patient
encounters. During this time period, 51% of providers offered a
counseling referral during at least half of their patient encounters.
Maintenance
Longer-term data on reach and effectiveness will be collected
every 6-months. Sustainability is often driven by a favorable
“implementation climate,” characterized by the extent to
which delivering tobacco treatment is expected, supported,
and rewarded. We believe the training strategies, data
transparency, and performance feedback will enhance
maintenance, as will the tactical design of ELEVATE as a
low-burden point-of-care decision support tool. The program
utilizes an embedded cancer care team, with no plans to
hire tobacco treatment specialists or additional staff. As a
result, there are no discrete costs for dedicated personnel, and




The Tobacco Treatment Service (TTS) at Smilow Cancer
Hospital in New Haven, CT was started in 2011 and expanded
in 2017 after receiving C3I funding to include several Cancer
Care Centers across Connecticut (Table 1). The TTS offers
smoking cessation counseling (in-person, televideo, or phone-
based), medication management, and referrals to the NCI
SmokefreeTXT program. EHR modifications improved the
identification and treatment of current smokers. Streamlining
the EHR tobacco use assessment section was proposed, but
would have required changes across the whole health system
and therefore was not accepted at the organizational level.
Due to this barrier, efforts were redirected toward revising
the BPA to increase utilization. The previously existing
BPA required multiple steps on the part of the provider
and ordered a TTS referral only. Through feedback from
providers and beta testing, the BPA was optimized to be
less disruptive to clinical workflows, include all necessary
steps and documentation in one click (i.e., diagnosis,
after visit summary, smoking counseling note, and CPT
billing code), and include the option to order tobacco
pharmacotherapies (i.e., varenicline or nicotine patches and
lozenges) using pre-populated fields based on the patient’s
current tobacco use.
Reach
EHR generated reports documented the number of current
smokers, and the number who were referred to the TTS
and/or prescribed cessation medication. The TTS received
notification of patients referred to SmokefreeTXT via a separate
reporting mechanism. Over a 6-month period after program
implementation, smoking prevalence among those screened was
18%. Among the documented current smokers, reach for the
Smilow Cancer Hospital and the Care Centers over 6 months was
7% (Table 2). Among those reached, 58.5% received in-person
counseling, and 97.4% received medications.
Effectiveness
Participants who receive counseling from the TTS are offered
follow-up visits after 6 months to assess and document
current smoking status in the EHR. Follow-up can be
challenging because some patients withdraw from the TTS,
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TABLE 2 | Pragmatic application of RE-AIM to evaluate tobacco treatment program implementation at three NCI-Designated Cancer Centers funded through the Cancer
Center Cessation Initiative.








REACH Smoking prevalenceb 12.5% 18% 21.1%
Smokers reached with at least one
evidence-based cessation treatment
43.1% of smokers were
prescribed cessation
medications and/or received brief
counseling at the point-of-care
7% of smokers were prescribed
cessation medications, referred
to the TTS, and/or referred to
SmokefreeTXT
24.3% of smokers were
prescribed cessation
medications, referred to TIPS,
and/or referred to SmokefreeTXT
EFFECTIVENESS Assessment method Tobacco use status from EHR for
most recent visit during
6-months period post-treatment
Assessed at 6-months in person
or via phone & documented in
EHR
Assessed at 6-months in person
or via phone and documented in
EHR.











ADOPTION Setting level adoption 21/21 outpatient oncology clinics
over a 6-months implementation
period.
Adopted at Smilow Cancer
Center and 9/10 Care Centers
over ∼8 months.
Adopted in 3/3 healthcare
systems. One launched
center-wide, two launched in
thoracic and gynecological
oncology clinics.
Provider level adoption 99% providers initiated
assessment, 79% initiated
documentation of medication,
85% initiated offer of counseling
referral.
Not assessed Number of referring providers (N
= 64) has increased by 25%
over 1 year of implementation.





93% providers achieved ≥90%
rate
Not assessed Not assessed
Implementation of key program
components
Pharmacotherapy rate: 49% of
providers achieve ≥20% rate;
Counseling offer rate: 51% of
providers achieve ≥50% rate
BPA utilization rates for referrals
to the TTS, pharmacotherapy or
both.
51% of referred patients received
at least one component of the
TIPS intervention.
MAINTENANCE Sustainability plans/goals • 6-months ongoing reach and
effectiveness evaluation.
• Incentivize care using data
transparency and performance
feedback.
• Low-burden, low cost decision
support tool for point-of-care
use ($3 per patient).
Hiring another tobacco treatment
specialist to maintain program at
Care Centers. Billing for services
using an APRN and expanding
telehealth services. Integrating
referrals into new patient
onboarding by nurse navigators.
• Leverage initial success.
• Generate new funding sources.
• Reduce patient barriers
to treatment (e.g. cost,
transportation.
• Identify 100% of smokers &
reach at least 50% of smokers
with treatment.
a Reported for a 6-month period at 1-year post-implementation.
bAmong patients screened for tobacco use.
c Average of three cancer healthcare settings.
TTS, Tobacco Treatment Service; TIPS, Tobacco Intervention & Psychosocial Support.
appointment availability may not always align with patients’
schedules, and there are limited resources to maintain contact.
Among those who completed 6-month follow-up visits (n
= 30 out of 223 participants), the 30-day point prevalence
abstinence rate was 16.7% (2.2% using an intent to treat
principle counting those lost to follow-up as current smokers)
(Table 2).
Adoption
Programmatic adoption occurred in stages. The TTS program
has been adopted at nine of 10 Smilow Cancer Care Settings
in addition to the Smilow Cancer Hospital. One site declined
to participate due to an established relationship with a smoking
cessation program at another local hospital. Care Centers were
visited by TTS staff to establish relationships with clinical and
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administrative staff, which facilitated the adoption of the new
clinical workflow. Adoption occurred over about 8 months, with
two to three Care Centers added every 1 to 2 months. This
gradual expansion allowed for piloting the BPA first in a few
sites, revealing a need to modify the EHR to allow for referrals
from RNs in addition to MDs and Advanced Practice Providers,
and a need for educational meetings with nursing staff. A TTS
“Champion” partner was identified at each Care Center to help
integrate services into the center.
Implementation
Rates of tobacco use assessment and documentation are
examined by clinical setting and by provider. The average tobacco
use assessment rate for a 6-month period was 49.5% across
settings, primarily because tobacco use assessment in the EHR is
not mandatory. Reports are generated to show: (1) the number of
times the BPA “fired,” or appeared to a provider (2) the number
of times the BPA “fired” and was acted on, and (3) the number
of acted on BPA fires that included a referral to the TTS only,
tobacco pharmacotherapy orders, or both. The data are then
used to identify settings or providers with lower BPA utilization
rates to provide feedback and troubleshoot barriers. For example,
at one Care Center, low utilization was due to limited staffing
following the departure of an oncologist. The remaining clinical
staff were unable to devote substantial resources to implementing
enhanced care for their patients who smoked, because their
patient loads had increased.
Maintenance
Currently, one staff member provides counseling services at nine
Care Centers on a rotating weekly schedule, traveling up to 900
miles per month. To maintain the program and increase capacity
for treatment provided at each site, another full-time APRN was
hired. As NCI grant funding comes to an end, Smilow Cancer
Hospital will take over funding for the TTS providers, who
will eventually bill for services. Additional maintenance efforts
include expanding telehealth options and working with nurse
navigators who onboard new cancer patients to integrate the TTS
into the standard treatment offered at Smilow.
Case Western Reserve University
Context
Case Comprehensive Cancer Center (Case CCC) serves 15
counties in Northeast Ohio. In Cleveland, the most populous
city in the catchment area, smoking prevalence (35%) and
lung cancer mortality rates exceed national averages. Case CCC
consists of Case Western Reserve University School of Medicine,
University Hospitals Seidman Cancer Center (SCC), Cleveland
Clinic Taussig Cancer Institute (TCI), and is closely affiliated
with the county safety-net hospital, MetroHealth Cancer Center
(MHCC). Together, these cancer centers see about 20,000 new
cancer cases annually and comprise a complex clinical setting
in which to implement change. Each health system sees a
distinct patient population, with underserved and racial/ethnic
minority cancer patients seen largely at MHCC. In 2017, the
Tobacco Intervention and Psychosocial Support (TIPS) Service
was implemented in all three health systems and was designed to
address the unique needs of cancer patients and survivors.
Clinicians screen for tobacco use and identify current
smokers using the EHR during new patient visits. The
tobacco use assessment questions were standardized across the
three healthcare settings based on NCCN guidelines (6). The
provider note includes a field to assess tobacco use status and
tobacco use history/nicotine dependence. For current users,
readiness to quit is assessed; relapse risk is assessed among
recent quitters/former smokers. EHR modifications included
programming to generate provider notes to summarize services
delivered. Current tobacco users who indicated willingness to
quit within the next 4 weeks are referred to TIPS either via an
EHR-based order for counseling, or via email/pager. Irrespective
of their willingness to participate in counseling, patients have the
option to be enrolled in SmokefreeTXT. TIPS delivers cessation
counseling using cognitive behavioral therapy combined with
FDA-approved pharmacotherapy. TIPS is tailored to cancer
patients by including cancer-specific psychoeducation, content
that addresses the emotional vulnerability of this population,
and flexible intervention formats (e.g., in-clinic, telephone,
combination). Caregivers, family members, and/or significant
others who use tobacco products are eligible for TIPS, and may
participate with the patient, or independently.
Reach
Reach was defined as the proportion of current smokers who
participated in TIPS, enrolled in SmokefreeTXT, and/or were
prescribed cessation medication. Over 6 months, the average
prevalence of current smoking was 21.1% among those screened,
and an average of 24.3% of smokers across the three sites
received at least one type of tobacco treatment (Table 2).
Pharmacotherapy was the most common treatment type (82.1%),
followed by in-person counseling (10.2%). Of note, 98% of
patients who received counseling or another intervention also
received pharmacotherapy.
Effectiveness
Effectiveness is assessed at 6-months after TIPS engagement.
Program staff contact patients to document their current
smoking status via telephone or interview patients in person if
they have a scheduled an appointment. An average of 54.4% of
TIPS participants were reached at 6-months follow-up across
the three healthcare settings, after 1 year of implementation.
Challenges to follow-up include patients being unreachable by
phone or not being scheduled for a clinic follow-up near the time
of assessment. Among TIPS patients with follow-up data, average
30-days abstinence at 6-month post-treatment was 35.1% across
the three sites. Using an intent-to-treat principle (assuming
patients lost to follow-up were still smoking) there was an average
30-day abstinence rate of 19.5%.
Adoption
The TIPS program was adopted in all three Case CCC
affiliated health systems. Two health systems focused the
initial implementation in thoracic and gynecological oncology
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clinics and the third opted for a center-wide launch. Pre-
implementation program site leaders and clinical champions
were instrumental to build clinical capacity, train staff, modify
the EHR to standardize the assessment and documentation of
tobacco use and treatment, and to integrate TIPS into the clinical
workflow. Several implementation strategies facilitated the
adoption of TIPS into the clinical workflow, including securing
support from clinical and administrative leadership, operations
staff, and IT specialists early in the process; seeking input from
providers and staff during clinical division meetings and grand
rounds; developing marketing strategies; and facilitating TIPS
staff and medical team engagement. Initial provider engagement
strategies have been encouraging, as the number of referring
providers (N = 64) has increased by 25% over the past year
with growing awareness of the service. Adoption challenges
included securing adequate space, buy-in from providers with
many competing responsibilities and limited time with patients,
and the lengthy period to implement requested additions to
the EHR.
Implementation
Implementation was assessed for the following elements key to
delivering the TIPS program: tobacco use screening, provider
referrals, and intervention delivery to smokers referred. The
average rate of tobacco use assessment was 80%, which was
negatively affected by EHR programming challenges at one of the
hospitals (we anticipate the rate will increase). Over a 6-month
period following implementation, 51.4% of patients referred to
TIPS completed the tobacco history assessment and at least one
intervention component of TIPS.
Maintenance
TIPS service adoption is ongoing in three cancer hospitals
that serve Northeast Ohio, the first regional effort to address
tobacco use in cancer care settings. To maintain TIPS, the
goal is to leverage the initial success of the effort, sustain EHR
modifications to facilitate assessment and referrals, develop new
strategies to increase provider and patient engagement, generate
funding sources, and examine strategies to reduce patient-level
barriers (e.g., cost/copays, transportation). The sustainability
goals are to identify 100% of current tobacco smokers (and recent
quitters), maintain an overall program reach of at least 50% of
eligible patients, and demonstrate abstinence rates that are at least
comparable to published estimates.
DISCUSSION
Using case studies from three funded C3I Cancer Centers,
this report describes the application of the RE-AIM framework
and the operationalization of each construct to evaluate the
implementation of a range of cessation services (e.g., counseling,
Quitline) in cancer care settings. The RE-AIM measures
proposed have implications for cancer care settings beyond
NCI Cancer Centers. The measures are flexible enough to
work in different settings and for different types of tobacco
treatment programs but are robust enough to measure intended
evaluation outcomes. The measures can be applied across
TABLE 3 | Summary of challenges to the measurement of RE-AIM within three





Reach Measurement relies on consistent documentation of patient
smoking status and engagement in tobacco treatment
services.
Effectiveness Follow-up measures (at 6-months post engagement) are
dependent upon patient availability and program staff and
resources to maintain follow-up contacts.
Adoption Measuring provider-level adoption is dependent upon
program and organizational resources to track and obtain
provider-specific reports from the EHR.
Implementation Measuring the implementation of key program components is
dependent on program resources to document and produce
reports using the EHR.
Maintenance Measuring maintenance and sustainability is dependent on
the program’s ability to measure the other RE-AIM
dimensions. Reporting on each of these measures over time
can help Cancer Centers understand the long term
sustainability of their program.
different healthcare systems and EHR platforms. C3I Centers
largely used the funding to enhance the EHR to identify and refer
smokers to treatment (19). As a result, the examples described
provide guidance on using the EHR to assess RE-AIM constructs
to evaluate the implementation of tobacco treatment programs
integrated into cancer care. Each Center identified common
challenges to measuring RE-AIM, or “lessons learned,” for other
cancer care settings to be aware of when implementing tobacco
treatment programs (Table 3).
Previous work has shown that systems level changes,
including EHR modifications, for assessing and referring
patients to treatment can result in increased tobacco use
documentation and counseling referrals (20–23). The profiled
Centers utilized the EHR to identify and refer smokers to
tobacco treatment services and to evaluate reach. Measuring
reach posed challenges. Documenting the denominator (the
number of current smokers) relies both on the consistent
documentation of smoking status, and a way to extract that
information from the EHR. Measuring the numerator for
reach requires defining and documenting program engagement.
At Washington University, the numerator included patients
prescribed cessation medication or who had received counseling
at the point-of-care. At Yale and Case, the reach numerator
included patients who participated in in-person or telephone
counseling, SmokefreeTXT, and/or were prescribed cessation
medication. Because the treatment offered differs, defining the
numerator is critical when making cross site comparisons. Reach
is likely greater at Washington University because cessation
counseling is delivered at the point-of-care, while the others refer
to a counseling program.
Measuring effectiveness posed a different set of challenges
(e.g., low rates of smoking status ascertainment), which may
limit information regarding quit rates (20). While assessment
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of long-term smoking status is challenging, the EHR provides
a highly efficient and cost-effective means of gathering follow-
up data on patients receiving treatment. Each Center used
the EHR to document tobacco use status at follow-up.
However, Washington University utilized the EHR as the
primary method to assess tobacco use with the patient’s
most recent visit at 6 months after tobacco treatment. The
others used in-person or phone follow-up as the primary
assessment. In reality, a combination of approaches may
be necessary, where patients are contacted at follow-up to
determine outcomes, but EHR-documented tobacco use status
could be used when patients are not reached. Capturing the
assessment of smoking outcomes in health system delivered
programs is vital since reduced smoking prevalence is a
key goal. Such data would yield meaningful outcomes upon
which different implementation and intervention strategies can
be compared.
In addition to reach and effectiveness, measuring
implementation and adoption was facilitated by generating
EHR reports for screening rates and provider-level program
referrals. Two Centers provided monthly provider and clinic
level performance data to show progress and identify areas for
improvement. Non-adopting sites or providers may signal local
barriers to initiation ranging from awareness, to self-perceived
competence, to lack of supporting resources. Implementation
strategies, such as staff training and practice facilitation, pairing
non-adopting sites with mentor sites to share knowledge and
resources, or identifying “champions” may be needed to address
barriers and increase site- and provider-level adoption rates.
Monthly data not only reflect adoption and implementation
across providers and clinics, but also show trajectories that
speak to maintenance. However, sites may be limited by
organizational capacity to report back provider-level adoption
and implementation metrics that may be useful for evaluation.
The evaluation of provider level measures could be built into the
EHR during program development, as making changes to the
EHR after the fact is often challenging.
There are some limitations to this study. The RE-AIM
application was examined within well-resourced Centers
receiving funding to implement tobacco treatment services;
however, it is unknown how readily less well-resourced
cancer care settings without robust health informatics support
could query the EHR to extract RE-AIM relevant data. The
profiled Centers engaged in EHR modifications permitting
efficient collection of evaluation measures, which may limit the
adoption of this RE-AIM approach given significant resource
requirements. Implementation at Washington University
coincided with the launch of a new EHR platform allowing for
more changes to the EHR than the other Centers. Data on reach
and effectiveness were collected by patient sociodemographics;
however, presenting this information was beyond the scope of
this paper. Information on cost was not available, however cost
data are being collected from C3I Centers and will be reported
to inform program implementation in other cancer care settings.
It is premature to report on the long-term maintenance of reach
and effectiveness among programs overall and across different
patient demographics. As programs mature, evaluation of
demographics may facilitate the adoption of programs to better
suit patient populations and is an important indicator of whether
programs are equitably reaching all cancer patients who smoke.
Delivering tobacco treatment to cancer patients who smoke
should be a routine and integrated part of cancer care (24). RE-
AIM provides a framework for multilevel program evaluation to
ensure patient benefit, provider performance, and organizational
commitment. RE-AIM provides a vital component of an
audit and feedback strategy by yielding performance data to
inform normative comparisons, rewards, and encouragement
to improve, along with existing resources and supports for
the lower-performing groups. Conducting routine RE-AIM
evaluations via the EHR allows program staff to rapidly identify
gaps in care and address barriers with targeted strategies.
A common RE-AIM approach to implementation assessment
allows for trans-program comparisons to identify effective
implementation and intervention strategies. The programs
described provide tobacco treatment program staff working in
cancer care settings with specific examples of measuring each
RE-AIM dimension using the EHR to facilitate measurement. In
summary, the measures demonstrate a pragmatic approach to
using RE-AIM as an evaluation framework that yields relevant
outcomes on common implementation metrics across widely
differing tobacco treatment approaches and cancer care settings.
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